Insulet’s next diabetes technology challenge is not control alone, it is usability at scale
Find out how Insulet’s Omnipod 6 and fully closed-loop data could reshape automated insulin delivery for diabetes care.
Find out how Insulet’s Omnipod 6 and fully closed-loop data could reshape automated insulin delivery for diabetes care.
Insulet's EVOLUTION 2 study shows 68% TIR with no boluses in type 2 diabetes. Analysis of what the FCL data means before the EVOLVE pivotal trial.
Medtronic’s MiniMed 780G now ships in the U.S. with Abbott’s Instinct sensor. Explore how this launch could reshape CGM-insulin system competition.